Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

Pharmacogenomics

Volumn 14, Issue 2, 2013, Pages 205-213

  Jensen, Brian C ^a   McLeod, Howard L ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

Author keywords

anthracyclines; antineoplastic agents; cardiomyopathy; dilated; heart failure; pharmacogenetics

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; DASATINIB; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GLUCOSE TRANSPORTER; IMATINIB; NATRIURETIC FACTOR; RAZOXANE; SORAFENIB; SUNITINIB; TRASTUZUMAB; TROPONIN;

ABCC1 GENE; AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; DRUG TRANSPORT; ECHOCARDIOGRAPHY; ERBB2 GENE; GENE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NCF4 GENE; NONHUMAN; PATIENT SELECTION; PHARMACOGENOMICS; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN TARGETING; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCINTIANGIOGRAPHY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC28A3 GENE; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARDIOTOXINS; GENETIC ASSOCIATION STUDIES; HEART FAILURE; HUMANS; PHARMACOGENETICS; RISK;

EID: 84872584938     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.205     Document Type: Article

References (78)

1. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259(14), 9182-9187 (1984). (Pubitemid 14098903)
2. Arcamone F, Cassinelli G, Fantini G et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 11(6), 1101-1110 (1969).
3. Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med. 80(2), 249-259 (1974).
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
5. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20(3), 333-353 (1967).
6. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(2), 302-314 (1973).
7. Bonadonna G, Monfardini S. Cardiac toxicity of daunorubicin. Lancet 1(7599), 837 (1969).
8. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710-717 (1979). (Pubitemid 10218041)
9. Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(12), 2629-2636 (2005). (Pubitemid 46179451)
10. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11), 2869-2879 (2003). (Pubitemid 36605157)
11. Kremer LC, Van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. 13(4), 503-512 (2002). (Pubitemid 34461132)
12. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann. Oncol. 22(5), 1011-1018 (2010).
13. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. 13(6), 819-829 (2002). (Pubitemid 34752678)
14. Wang TJ, Evans JC, Benjamin EJ, Levy D, Leroy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108(8), 977-982 (2003). (Pubitemid 37048228)
15. Kopp LM, Bernstein ML, Schwartz CL et al. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS). J. Clin. Oncol. 30(Suppl.), Abstract 9503 (2012).
16. Landy DC, Miller TL, Lopez-Mitnik G et al. Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Am. Heart J. 163(2), 295-301 e292 (2012).
17. Lipshultz SE, Landy DC, Lopez-Mitnik G et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J. Clin. Oncol. 30(10), 1050-1057 (2012).
18. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 25(25), 3808-3815 (2007). (Pubitemid 47477254)
19. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26(22), 3777-3784 (2008).
20. Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol. Ther. 125(2), 196-218 (2010).
21. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol. 7(2), 114-121 (2007). (Pubitemid 47339857)
22. Zhao Y, Mclaughlin D, Robinson E et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res. 70(22), 9287-9297 (2010).
23. Cole MP, Chaiswing L, Oberley TD et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc. Res. 69(1), 186-197 (2006). (Pubitemid 41814822)
24. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest. 108(4), 585-590 (2001). (Pubitemid 32777738)
25. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest. 100(6), 1501-1506 (1997). (Pubitemid 27425776)
26. Shioji K, Kishimoto C, Nakamura H et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106(11), 1403-1409 (2002). (Pubitemid 35013046)
27. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc. Natl Acad. Sci. USA 101(18), 6975-6980 (2004). (Pubitemid 38596428)
28. Kim Y, Ma AG, Kitta K et al. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 63(2), 368-377 (2003). (Pubitemid 36158372)
29. Kunisada K, Negoro S, Tone E et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl Acad. Sci. USA 97(1), 315-319 (2000). (Pubitemid 30055828)
30. Lien YC, Noel T, Liu H, Stromberg AJ, Chen KC, St Clair DK. Phospholipase C-delta1 is a critical target for tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury. Cancer Res. 66(8), 4329-4338 (2006).
31. Niu J, Azfer A, Wang K, Wang X, Kolattukudy PE. Cardiac-targeted expression of soluble fas attenuates doxorubicin-induced cardiotoxicity in mice. J. Pharmacol. Exp. Ther. 328(3), 740-748 (2009).
32. Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM- p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J. Mol. Cell. Cardiol. 47(5), 698-705 (2009).
33. Speyer JL, Green MD, Kramer E et al. Protective effect of the bispiperazinedione ICRF 187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med 319(12), 745-752 (1988).
34. Marty M, Espie M, Llombart A, Monnier A, Rapoport BL, Stahalova V. Multicenter randomized Phase III study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol. 17(4), 614-622 (2006).
35. Miranda CJ, Makui H, Soares RJ et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102(7), 2574-2580 (2003). (Pubitemid 37193598)
36. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7(10), 564-575 (2010).
37. Lipshultz SE, Miller TL, Scully RE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J. Clin. Oncol. 30(10), 1042-1049 (2012).
38. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J. Am. Coll. Cardiol. 56(20), 1644-1650 (2010).
39. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med 344(11), 783-792 (2001). (Pubitemid 32222155)
40. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102(3), 272-274 (2000). (Pubitemid 30457574)
41. Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med 353(16), 1659-1672 (2005). (Pubitemid 41464705)
42. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med 365(14), 1273-1283 (2011).
43. Guglin M, Hartlage G, Reynolds C, Chen R, Patel V. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J. Card. Fail. 15(8), 651-657 (2009).
44. Tarantini L, Cioffi G, Gori S et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J. Card. Fail. 18(2), 113-119 (2012).
45. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25(23), 3525-3533 (2007). (Pubitemid 47310891)
46. Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30(31), 3792-3799 (2012).
47. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J. Am. Coll. Cardiol. 60(24), 2504-2512 (2012).
48. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23(31), 7820-7826 (2005). (Pubitemid 46657379)
49. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116(8), 954-960 (2007). (Pubitemid 47300920)
50. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007). (Pubitemid 350236338)
51. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7(5), 332-344 (2007). (Pubitemid 46652481)
52. Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120(1), 14-32 (2011).
53. Mcgonigle KF, Muntz HG, Vuky J. et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a Phase 2 study. Cancer 117(16), 3731-3740 (2011).
54. Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ. Res. 109(12), 1401-1409 (2011).
55. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12), 1672-1677 (1991).
56. Hershman DL, Mcbride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse Bcell non-Hodgkin's lymphoma. J. Clin. Oncol. 26(19), 3159-3165 (2008).
57. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med 332(26), 1738-1743 (1995).
58. Serrano C, Cortes J, De Mattos-Arruda L et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann. Oncol. 23(4), 897-902 (2012).
59. Henderson IC, Allegra JC, Woodcock T et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7(5), 560-571 (1989). (Pubitemid 19126791)
60. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10(2), 111-126 (2011).
61. Beauclair S, Formento P, Fischel JL et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann. Oncol. 18(8), 1335-1341 (2007). (Pubitemid 47305006)
62. Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J. Mol. Cell. Cardiol. 51(4), 518-528 (2011).
63. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 60(18), 5158-5164 (2000).
64. Dell'acqua G, Polishchuck R, Fallon JT, Gordon JW. Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum. Gene Ther. 10(8), 1269-1279 (1999). (Pubitemid 29267582)
65. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24), 3754-3762 (2005). (Pubitemid 43739516)
66. Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large Bcell lymphoma treated with R-CHOP21. Leukemia 23(6), 1118-1126 (2009).
67. Blanco JG, Leisenring WM, Gonzalez- Covarrubias VM et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112(12), 2789-2795 (2008). (Pubitemid 351969225)
68. Semsei AF, Erdelyi DJ, Ungvari I et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol. Int. 36(1), 79-86 (2012).
69. Rajic V, Aplenc R, Debeljak M et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk. Lymphoma 50(10), 1693-1698 (2009).
70. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422-1428 (2011).
71. Zambelli A, Della Porta MG, Eleuteri E et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast 20(2), 176-183 (2010).
72. Sterba M, Popelova O, Lenco J et al. Proteomic insights into chronic anthracycline cardiotoxicity. J. Mol. Cell. Cardiol. 50(5), 849-862 (2011).
73. Xia L, Jaafar L, Cashikar A, Flores-Rozas H. Identification of genes required for protection from doxorubicin by a genome-wide screen in Saccharomyces cerevisiae. Cancer Res. 67(23), 11411-11418 (2007). (Pubitemid 350248569)
74. Duan S, Bleibel WK, Huang RS et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67(11), 5425-5433 (2007). (Pubitemid 46997283)
75. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med 364(12), 1144-1153 (2011).
76. Montemurro F, Rossi V, Nole F et al. Underuse of anthracyclines in women with HER-2+ advanced breast cancer. Oncologist 15(7), 665-672 (2010).
77. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 24(34), 5381-5387 (2006). (Pubitemid 46623169)
78. Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J. Clin. Oncol. 29(6), 632-638 (2011).